Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF

Vaccine

Volumn 29, Issue 11, 2011, Pages 2131-2139

  Krause, Anja ^a   Whu, Wen Zhu ^a   Xu, Yaqin ^a   Joh, Ju ^a   Crystal, Ronald G ^a   Worgall, Stefan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Mucosal immunity; Pseudomonas; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN F; PSEUDOMONAS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMORAL IMMUNITY; LUNG; LUNG ALVEOLUS EPITHELIUM; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SPLEEN; SURVIVAL; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; FEMALE; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED C57BL; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; T-LYMPHOCYTES;

EID: 79951811903     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.087     Document Type: Article

References (76)

1. Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002, 15(2):194-222.
2. Stryjewski M.E., Sexton D.J. Severe Infections Caused by Pseudomonas aeruginosa 2003, 1-15. Kluwer Academic, Boston. A.R. Hauser, J. Rello (Eds.).
3. Stanislavsky E.S., Lam J.S. Pseudomonas aeruginosa antigens as potential vaccines. FEMS Microbiol Rev 1997, 21:243-277.
4. Matthews-Greer J.M., Gilleland H.E. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J Infect Dis 1987, 155:1282-1291.
5. Moon M.M., Hazlett L.D., Hancock R.E., Berk R.S., Barrett R. Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci 1988, 29(8):1277-1284.
6. Price B.M., Galloway D.R., Baker N.R., Gilleland L.B., Staczek J., Gilleland H.E. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect Immun 2001, 69(5):3510-3515.
7. Gilleland H.E., Gilleland L.B., Staczek J., Harty R.N., Garcia-Sastre A., Palese P., et al. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection. FEMS Immunol Med Microbiol 2000, 27:291-297.
8. Bumann D., Behre C., Behre K., Herz S., Gewecke B., Gessner J.E., et al. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 2010, 28(3):707-713.
9. Gocke K., Baumann U., Hagemann H., Gabelsberger J., Hahn H., Freihorst J., et al. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol Med Microbiol 2003, 37(2-3):167-171.
10. Hancock R.E., Mouat E.C., Speert D.P. Quantitation and identification of antibodies to outer-membrane proteins of Pseudomonas aeruginosa in sera of patients with cystic fibrosis. J Infect Dis 1984, 149(2):220-226.
11. Jang I.J., Kim I.S., Park W.J., Yoo K.S., Yim D.S., Kim H.K., et al. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine 1999, 17:158-168.
12. Kim D.K., Kim J.J., Kim J.H., Woo Y.M., Kim S., Yoon D.W., et al. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine 2000, 19(December (9-10)):1274-1283.
13. Larbig M., Mansouri E., Freihorst J., Tummler B., Kohler G., Domdey H., et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 2001, 19:2291-2297.
14. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.D., et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun 1999, 67:1461-1470.
15. Worgall S., Krause A., Qiu J., Joh J., Hackett N.R., Crystal R.G. Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol 2007, 81(24):13801-13808.
16. Hackett N.R., Kaminsky S.M., Sondhi D., Crystal R.G. Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther 2000, 2(4):376-382.
17. Jooss K., Yang Y., Fisher K.J., Wilson J.M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998, 72(5):4212-4223.
18. Jooss K., Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003, 10(11):955-963.
19. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.S., Choppin J., Gahery-Segard H., et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002, 76(1):127-135.
20. D'Ambrosio E., Del Grosso N., Chicca A., Midulla M. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J Hyg Lond 1982, 89(1):155-161.
21. Hofmann C., Loser P., Cichon G., Arnold W., Both G.W., Strauss M. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol 1999, 3(8):6930-6936.
22. Molnar-Kimber K.L., Sterman D.H., Chang M., Kang E.H., El Bash M., Lanuti M., et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998, 9(14):2121-2133.
23. Piedra P.A., Poveda G.A., Ramsey B., McCoy K., Hiatt P.W. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998, 101(6):1013-1019.
24. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77(15):8263-8271.
25. Bangari D.S., Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006, 24(7):849-862.
26. Seregin S.S., Amalfitano A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin Biol Ther 2009, 9(12):1521-1531.
27. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol Ther 2009, 17(8):1333-1339.
28. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002, 76(6):2667-2675.
29. Farina S.F., Gao G.P., Xiang Z.Q., Rux J.J., Burnett R.M., Alvira M.R., et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001, 75(23):11603-11613.
30. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170(3):1416-1422.
31. Mittal S.K., Prevec L., Graham F.L., Babiuk L.A. Development of a bovine adenovirus type 3-based expression vector. J Gen Virol 1995, 76(Pt 1):93-102.
32. Moffatt S., Hays J., Hogen E.H., Mittal S.K. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 2000, 272(1):159-167.
33. Pinto A.R., Fitzgerald J.C., Giles-Davis W., Gao G.P., Wilson J.M., Ertl H.C. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 2003, 171:6774-6779.
34. Reddy P.S., Idamakanti N., Hyun B.H., Tikoo S.K., Babiuk L.A. Development of porcine adenovirus-3 as an expression vector. J Gen Virol 1999, 80(Pt 3):563-570.
35. Reyes-Sandoval A., Fitzgerald J.C., Grant R., Roy S., Xiang Z.Q., Li Y., et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 2004, 78(14):7392-7399.
36. Roy S., Gao G., Lu Y., Zhou X., Lock M., Calcedo R., et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther 2004, 15(5):519-530.
37. Basnight M., Rogers N.G., Gibbs C.J., Gajdusek D.C. Characterization of four new adenovirus serotypes isolated from chimpanzee tissue explants. Am J Epidemiol 1971, 94(2):166-171.
38. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006, 12(10):1596-1599.
39. Dudareva M., Andrews L., Gilbert S.C., Bejon P., Marsh K., Mwacharo J., et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009, 27(27):3501-3504.
40. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 2004, 10(4):616-629.
41. Pinto A.R., Fitzgerald J.C., Gao G.P., Wilson J.M., Ertl H.C. Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine 2004, 22(5-6):697-703.
42. Ertl H.C. Immunological insights from genetic vaccines. Virus Res 2005, 111(1):89-92.
43. Santra S., Sun Y., Korioth-Schmitz B., Fitzgerald J., Charbonneau C., Santos G., et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 2009, 27(42):5837-5845.
44. Hashimoto M., Boyer J.L., Hackett N.R., Wilson J.M., Crystal R.G. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infection and Immunity 2005, 73(10):6885-6891.
45. Hersh J., Crystal R.G., Bewig B. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther 1995, 2(2):124-131.
46. Mittereder N., March K.L., Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996, 70(11):7498-7509.
47. Rosenfeld M.A., Yoshimura K., Trapnell B.C., Yoneyama K., Rosenthal E.R., Dalemans W., et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992, 68(1):143-155.
48. Kikuchi T., Worgall S., Singh R., Moore M.A., Crystal R.G. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat Med 2000, 6(10):1154-1159.
49. Worgall S., Busch A., Rivara M., Bonnyay D., Leopold P.L., Merritt R., et al. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 2004, 78:2572-2580.
50. Pier G. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev Vaccines 2005, 4(5):645-656.
51. Worgall S., Kikuchi T., Singh R., Martushova K., Lande L., Crystal R.G. Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells. Infect Immun 2001, 69(7):4521-4527.
52. Porwoll J.M., Gebel H.M., Rodey G.E., Markham R.B. In vitro response of human T cells to Pseudomonas aeruginosa. Infect Immun 1983, 40(2):670-674.
53. Dunkley M.L., Clancy R.L., Cripps A.W. A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. Immunology 1994, 83(3):362-369.
54. Stevenson M.M., Kondratieva T.K., Apt A.S., Tam M.F., Skamene E. In vitro and in vivo T cell responses in mice during bronchopulmonary infection with mucoid Pseudomonas aeruginosa. Clin Exp Immunol 1995, 99(1):98-105.
55. Hartl D., Griese M., Kappler M., Zissel G., Reinhardt D., Rebhan C., et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006, 117(1):204-211.
56. Moser C., Jensen P.O., Kobayashi O., Hougen H.P., Song Z., Rygaard J., et al. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol 2002, 127(2):206-213.
57. Cohen C.J., Xiang Z.Q., Gao G.P., Ertl H.C.J., Wilson J.M., Bergelson J.M. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol 2002, 83(1):151-155.
58. Varnavski A.N., Schlienger K., Bergelson J.M., Gao G.P., Wilson J.M. Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Hum Gene Ther 2003, 14(April (6)):533-544.
59. Kyd J.M., Foxwell A.R., Cripps A.W. Mucosal immunity in the lung and upper airway. Vaccine 2001, 19(17-19):2527-2533.
60. Lavelle E.C. Generation of improved mucosal vaccines by induction of innate immunity. Cell Mol Life Sci 2005, 62(23):2750-2770.
61. Twigg H.L. Humoral immune defense (antibodies): recent advances. Proc Am Thorac Soc 2005, 2(5):417-421.
62. Pilette C., Ouadrhiri Y., Godding V., Vaerman J.P., Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J 2001, 18(3):571-588.
63. Mestecky J., Russell M.W., Elson C.O. Perspectives on mucosal vaccines: is mucosal tolerance a barrier?. J Immunol 2007, 179(9):5633-5638.
64. Holmgren J., Harandi A.M., Czerkinsky C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev Vaccines 2003, 2:205-217.
65. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(4 Suppl.):S45-S53.
66. Vajdy M., Srivastava I., Polo J., Donnelly J., O'Hagan D., Singh M. Mucosal adjuvants and delivery systems for protein-DNA- and RNA-based vaccines. Immunol Cell Biol 2004, 82(6):617-627.
67. Park K.S., Lee J., Ahn S.S., Byun Y.H., Seong B.L., Baek Y.H., et al. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 2009, 395(2):182-189.
68. Lemiale F., Kong Wp, Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003, 77(18):10078-10087.
69. Baig J., Levy D.B., McKay P.F., Schmitz J.E., Santra S., Subbramanian R.A., et al. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol 2002, 76(22):11484-11490.
70. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80(4):1959-1964.
71. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367(9509):475-481.
72. Hoelscher M.A., Jayashankar L., Garg S., Veguilla V., Lu X., Singh N., et al. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Ther 2007, 82(6):665-671.
73. Croyle M.A., Patel A., Tran K.N., Gray M., Zhang Y., Strong J.E., et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008, 3(10):e3548.
74. Kim S., Jang J.E., Yu J.R., Chang J. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Vaccine 2010, 28(22):3801-3808.
75. Guo L., Wang J., Zhou H., Si H., Wang M., Song J., et al. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. Vaccine 2008, 26(4):460-468.
76. Macpherson A.J., McCoy K.D., Johansen F.E., Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008, 1(1):11-22.